FDA Approves First Gene Therapy for Genetic Hearing Loss in Children and Adults
Otarmeni restores natural hearing in patients with OTOF gene mutations — and Regeneron will offer it free in the U.S.
Summary
The FDA has granted accelerated approval to lunsotogene parvec (Otarmeni), the first gene therapy for genetic hearing loss caused by mutations in the OTOF gene. This ultra-rare condition affects roughly 50 newborns annually in the U.S. and previously had no cure. The therapy delivers a functional OTOF gene directly into inner ear hair cells via a single surgical infusion, restoring the otoferlin protein needed for auditory signaling. In clinical trials, 16 of 20 participants achieved meaningful hearing improvements within 24 weeks, and 42% of long-term responders reached normal hearing levels. Maker Regeneron has committed to providing the treatment at no cost to eligible U.S. patients. This approval marks a significant milestone in gene therapy and opens the door to treating other forms of genetic hearing loss.
Detailed Summary
The FDA's accelerated approval of lunsotogene parvec (Otarmeni) marks a landmark moment in genetic medicine — the first gene therapy cleared for hearing loss. For patients born with biallelic OTOF gene mutations, a condition that previously meant permanent deafness manageable only with devices, this one-time treatment now offers the possibility of restored natural hearing.
The therapy uses an adeno-associated virus (AAV) vector to deliver a working copy of the OTOF gene directly into the inner ear's hair cells. This restores production of otoferlin, a protein essential for transmitting sound signals from sensory cells to the auditory nerve. The procedure is administered surgically via intracochlear infusion — a technique similar to cochlear implantation — and can be performed in infants as young as 10 months.
In the ongoing phase I/II CHORD trial, 16 of 20 participants achieved hearing thresholds at or below 70 dB HL — the standard cutoff for avoiding cochlear implantation — within 24 weeks. Five of 12 long-term responders (42%) reached normal hearing, including the ability to detect whispers at 25 dB or below. All 12 patients followed for 48 weeks maintained their hearing gains, suggesting durable benefit from a single dose.
The most common side effects included ear infections, nausea, vomiting, dizziness, and procedural pain. The FDA noted that continued approval depends on confirming long-term durability and effects on speech development and quality of life. The label carries no contraindications.
For the broader longevity and health optimization community, this approval signals a maturing gene therapy pipeline capable of addressing sensory decline — a domain increasingly linked to cognitive health and quality of life with aging. Hearing loss is a known risk factor for cognitive decline and social isolation, making effective treatments relevant well beyond pediatric populations.
Key Findings
- Single-dose gene therapy restored hearing in 16 of 20 trial participants within 24 weeks
- 42% of long-term responders achieved normal hearing, including detecting whispers at 25 dB
- All 12 patients followed for 48 weeks maintained hearing improvements with no loss of effect
- Regeneron will provide Otarmeni at no cost to eligible U.S. patients
- First gene therapy approved under FDA Commissioner's National Priority Voucher pilot program
Methodology
This is a news report from MedPage Today summarizing an FDA approval announcement and associated clinical trial data. The source is a credible medical news outlet targeting healthcare professionals. Evidence is based on interim data from the ongoing phase I/II CHORD trial (n=20), with accelerated approval contingent on further confirmatory outcomes.
Study Limitations
Accelerated approval means long-term durability and effects on speech development remain unconfirmed and are still being assessed. The trial sample size is very small (n=20), and the condition is ultra-rare (~50 U.S. births/year), limiting generalizability. This approval applies only to OTOF-related deafness and does not extend to other genetic or age-related forms of hearing loss.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.